The FDA has posted a notice about the recall of continuous glucose monitors from Abbott.
The federal spending package that ended January’s government shutdown will prohibit PBMs from linking rebates to drug companies’ list prices. The FTC reported that PBMs inflated the prices of generic drugs.
The FDA has posted a notice for a dietary supplement recalls involving products found to contain undeclared pharmaceutical ingredients.
PSM Executive Director Shabbir Imber Safdar released the following statement in response to news that Hims & Hers is now compounding pill versions of a newly approved GLP-1 weight-loss drug.
This post outlines practical steps Congress should take to strengthen pharmaceutical border security, reinforce regulatory oversight, and protect patients.
A patient at a North Dakota med spa told investigators she had to coach the clinic owner through the IV administration process. The owner allegedly presented herself as a registered nurse, despite holding no medical licenses.
The bill will protect Iowa’s patients by closing enormous regulatory gaps in the med spa and wellness industry.
Our podcast covers the latest in pharma crime and medicine safety.
Like your information on video? Subscribe to our YouTube playlist!
Regulatory confusion leaves med spa patients at risk. Learn more.
Gaps in FDA oversight of 503B compounding facilities put patients at risk.
More fake Ozempic in the U.S. Learn more.
Click the images below to see more recent videos.